Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company focused on transforming biomedical inventions into cutting-edge therapies. The company develops novel therapies
Categories
biopharma
Ocean Biomedical announces loan commitment of up to $10 million from largest stockholder
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers to develop and commercialize their discoveries,
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Ocean Biomedical (OCEA) announces new findings in relation to treatment options for Hermansky-Pudlak Syndrome
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) announced its commitment to developing viable treatment options for Hermansky-Pudlak Syndrome (HPS) on Thursday. The
Infographic: Ocean Biomedical Inc. (OCEA) quarter ended June 30, 2022
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here are the company’s numbers for
AbbVie sees near-term slowdown; looks prepared to tackle patent expiration
AbbVie, Inc. (NYSE: ABBV) has delivered yet another quarter of strong top-line and earnings performance but issued cautious guidance for fiscal 2023
Infographic: Highlights of Gilead Sciences (GILD) Q4 2022 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when
Avid Bioservices Inc (CDMO) Q2 2023 Earnings Call Transcript
Avid Bioservices Inc (NASDAQ:CDMO) Q2 2023 Earnings Call dated Dec. 07, 2022. Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President & Chief Executive
Is Merck & Co. (MRK) a good investment after Q1 earnings?
Merck & Co., Inc. (NYSE: MRK) is recovering from the virus-induced slowdown supported by stable demand across its product line globally, a
ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) Q4 2021 earnings call dated Mar. 15, 2022 Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President and Chief
AbbVie (ABBV) Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) today reported its fourth-quarter financial results for the period ended December 31, 2021. Net revenues increased 7.4% to $14.8
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing
Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook
Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also
AbbVie (ABBV) stock research summary | Q3 2021
The AlphaStreet research report provides actionable data and insights into AbbVie’s fundamentals, the industry, and competition. The report is meant as a
Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ: CARA) Q3 2021 earnings call dated Nov. 08, 2021 Corporate Participants: Will Gramig -- Senior Analyst Derek Chalmers -- Chief Executive Officer,
Earnings: AbbVie (ABBV) Q3 profit rises, beats estimates on higher revenues
Biopharmaceutical company AbbVie Inc. (NYSE: ABBV) on Friday said its third-quarter revenues and net profit increased from last year. The results also
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13%
IPO news: Cingulate is making its market debut this week, here’s what to know
The biopharmaceuticals market was valued at approx. $325.17 billion in 2020 and it is expected to grow at a CAGR of 7.3%
IPO News: Here are a few things to note when Dice Therapeutics goes public
Many pharma companies are lining up to go public and this week will see Dice Therapeutics join the group. The California-based firm,
AbbVie (ABBV) Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) today reported its second-quarter financial results for the period ended June 30, 2021. Net revenues increased 34% to $13.9
Infographic: Highlights of Gilead Sciences (GILD) Q2 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its second-quarter 2021 earnings today after the closing bell. The revenue increased by 21%